Patients must meet all of the following inclusion criteria to be eligible for inclusion in
1. Confirmed diagnosis of AML on or after 01 January 2012 through Clinical Research Nurse
(CRN) review of provider documentation of AML diagnosis in the medical record.
2. Receipt of non-intensive therapy at any point during first line therapy following
initial AML diagnosis. For this study, non-intensive therapy will be defined as 1 of
the following agents, alone or in combination with any other agent:
3. Age ≥18 years at initial diagnosis of AML.
Patients meeting any of the following criteria will not be included in the study:
1. Record of 1 or more of the following confounding diagnoses at any point before or after
AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive
systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia;
dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.